153 citations,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
147 citations,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
147 citations,
April 1990 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride safely lowers DHT levels without affecting testosterone.
127 citations,
July 2002 in “EMBO journal” Normal skin cell renewal doesn't need RAR signaling, but vitamin A-related skin thickening does.
124 citations,
March 2012 in “JAMA” Testosterone's muscle-building effects do not require its conversion to DHT.
102 citations,
July 2020 in “International journal of molecular sciences” Hormones like testosterone and estrogen significantly affect hair growth and structure.
101 citations,
April 1994 in “Baillière's clinical endocrinology and metabolism” 5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
97 citations,
April 2016 in “Andrology” Hormones and metabolism play a complex role in prostate enlargement, and more research is needed to improve diagnosis and treatment.
93 citations,
February 2009 in “Annals of the New York Academy of Sciences” 5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.
90 citations,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.